Aggressive Treatment De-Escalation Feasible in HPV-Positive Oropharyngeal Cancer?

Video
Conference|American Society for Radiation Oncology Annual Meeting (ASTRO)

This video highlights 2-year results of a phase II study evaluating aggressive adjuvant chemoradiation dose de-escalation in HPV-positive oropharynx squamous cell carcinoma.

In this video, Daniel J. Ma, MD, of the Mayo Clinic in Rochester, Minnesota, discusses 2-year results of a phase II study evaluating aggressive adjuvant chemoradiation dose de-escalation in HPV-positive oropharynx squamous cell carcinoma.

Ma presented results of the study (abstract LBA-14) at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting, held September 24–27 in San Diego.

Recent Videos
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
Increased use of systemic therapies, particularly among patients with high-risk node-negative NSCLC, were observed following radiotherapy.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
Interest in novel therapies to improve outcomes initiated an investigation of the use of immunotherapy in early-stage non-small cell lung cancer.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Related Content
The cumulative chronic grade 3 or higher toxicity rate was 3% in patients treated with de-escalated adjuvant radiotherapy vs 11% with standard of care therapy.

DART Therapy Exhibits Greater Tolerability in Oropharyngeal SCC

Roman Fabbricatore
September 3rd 2025
Article

The cumulative chronic grade 3 or higher toxicity rate was 3% in patients treated with de-escalated adjuvant radiotherapy vs 11% with standard of care therapy.

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David J. Sher, MD, MPH
September 15th 2017
Podcast

In this interview we discuss new clinical guidelines from ASTRO on the use of radiotherapy in treating oropharyngeal cancer.

In June 2025, the FDA approved pembrolizumab in the same indication for HNSCC.2

Health Canada Approves Pembrolizumab/Surgery in Locally Advanced HNSCC

Tim Cortese
August 15th 2025
Article

Results from the phase 3 KEYNOTE-689 trial supported the agency’s approval of the pembrolizumab/surgery regimen in PD-L1–positive head and neck cancer.

A Phase 2 Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and Neck

A Phase 2 Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and Neck

Omar K. Abughanimeh, MBBS;Nicole A. Shonka, MD;Jane Meza, PhD;Lynette Smith, PhD;Irfan A. Vaziri, MD;Mehmet Sitki Copur, MD;Robin High, MBA;Kimberly Shields, BSN, RN;Holly DeSpiegelaere, BSN, RN;Anne Kessinger, MD;Apar Kishor Ganti, MD, MS
August 13th 2025
Article

This study explores the efficacy and safety of combining docetaxel and capecitabine for treating recurrent or metastatic head and neck cancer.

Data from the RATIONALE-309 trial support the European Commission’s approval of frontline tislelizumab plus chemotherapy in this patient population.

Tislelizumab/Chemotherapy Earns EU Approval in Nasopharyngeal Carcinoma

Russ Conroy
July 11th 2025
Article

Data from the RATIONALE-309 trial support the European Commission’s approval of frontline tislelizumab plus chemotherapy in this patient population.

No tracer-related adverse effects were observed in the study, with [18F]AIF-NOTA-PCP2 showing acceptable dosimetry in patients with head and neck cancers.

[18F]AIF-NOTA-PCP2 Shows PD-L1 Monitoring Potential in Head and Neck Cancer

Roman Fabbricatore
July 6th 2025
Article

No tracer-related adverse effects were observed in the study, with [18F]AIF-NOTA-PCP2 showing acceptable dosimetry in patients with head and neck cancers.